Published 19 December 2024 This call consists of prioritized health technology topics under the HTA general track and are proceeding to the following assessments: The Health Technology Assessment (HTA) Philippines invites interested researchers to submit capsule proposals under the HTA Research Agenda Program: 2024 HTA Topics – Batch 4 Call [FEC topics and Cycle 1 continue reading : CALL FOR PROPOSALS: HTA Research Agenda Program [HTA Research Topics 2024 – Batch 4 (FEC topics and Cycle 1 topics for Economic Assessments and Ethical, Legal, Social, and Health Systems Implication (ELSHI) Assessments; and, Cycle 2 topics for Clinical Assessments]
[FOR PUBLIC CONSULTATION] DRAFT Philippines Guidance Document for the Use of Real-World Evidence in Clinical Assessment of Health Technologies
Published on 11 December 2024 This is to update all our stakeholders that the Health Technology Assessment (HTA) Division has completed the Philippine Guidance Document on the Use of Real-World Evidence in Clinical Assessment of Health Technologies [DRAFT]. This is part of our ongoing efforts to develop specific HTA Method Guides across different health technologies. continue reading : [FOR PUBLIC CONSULTATION] DRAFT Philippines Guidance Document for the Use of Real-World Evidence in Clinical Assessment of Health Technologies
Tocilizumab for treatment of COVID-19 (2021 Assessment)
Return to Latest Recommendation
HTA Council Recommendation on Bivalent COVID-19 Vaccines as Booster
HTA Council Recommendation on Bivalent COVID-19 Vaccines as booster Date of OIC-SOH Approval: 25 April 2023 This assessment followed the HTA Council evaluation framework to evaluate COVID-19 vaccines using the following criteria: (1) responsiveness to magnitude and severity; (2) clinical efficacy and safety; (3) affordability, viability and feasibility; (4) household financial impact; (5) social impact; and continue reading : HTA Council Recommendation on Bivalent COVID-19 Vaccines as Booster
SOH Decision: Tocilizumab for the Treatment of COVID-19
Return to Main Page SOH approves the HTAC recommendation on tocilizumab for COVID-19 in the Philippine National Formulary (PNF) The Secretary of Health (SOH) approved the HTAC recommendation on the addition of tocilizumab for COVID-19 in the Philippine National Formulary (PNF) on 11 May 2022. On 15 March 2022, the Philippine FDA issued the CPR of tocilizumab continue reading : SOH Decision: Tocilizumab for the Treatment of COVID-19